頁籤選單縮合
題 名 | 三合一降血壓藥的療效和安全=Efficacy and Safety of Triple Therapy in Hypertension |
---|---|
作 者 | 黃美嫆; 汪忠炫; | 書刊名 | 藥學雜誌 |
卷 期 | 31:2=123 2015.06[民104.06] |
頁 次 | 頁50-56 |
分類號 | 418.221 |
關鍵詞 | 高血壓; 降血壓藥物; Blood pressure; Anti-hypertension therapy; Fixed-dose combination therapy; Single pill combination; Triple therapy; |
語 文 | 中文(Chinese) |
中文摘要 | 高血壓是增加心血管及腦血管疾病發病率和死亡率的危險因素。高血壓致病機 轉很多,多數病人需同時服用2-3種不同機轉的降血壓錠劑;但病人常因服用的藥 物顆數多又複雜,導致服藥遵囑性低,造成血壓控制不佳。本研究目標主探討新藥 『三合一』固定劑量組合劑型 Sevikar HCT (olmesartan 20 mg, amlodipine 5 mg, and hydrochlorothiazide 12.5 mg,fixed-dose combination),對治療高血壓的療效及安全性 評估。以回溯性方法收集2012年7月至2013年2月間,103位已服降壓藥仍控制不佳的 病人改用單錠 Sevikar HCT 治療,追蹤第4週、第8週、第12週的血壓變化,將所收集 資料以 SPSS 17進行資料分析。103位高血壓病人基本特徵:平均年齡65.4±13.3歲, 平均收縮/舒張血壓164.1 ± 20.1/90.6 ± 16.3 mmHg。103位病人併有第2型糖尿病有55 人 (53.9%) 為最多,併有高血脂有44人 (42.7%) 次之。病人服用 (二藥合一) 單錠複方 加單錠單方藥有32人 (31.1%),(二藥合一)單錠複方藥有26人 (25.2%),三種單錠單方 藥有25人 (24.3%)。病人改 Sevikar HCT 治療後第4週、第8週、第12週平均降收縮壓 分別為 ( 16 vs 16 vs 17 mmHg,P < 0.005);降舒張壓分別為 ( 8 vs 9 vs 9 mmHg, P < 0.005)。副作用主要是下肢水腫3人 (2.91%),胃腸功能障礙3人 (2.91%)。當發現 有難控制的血壓及藥物遵醫囑性或服藥順從性不佳的病人,新藥固定劑量組合的『三 合一』藥提供另一降血壓藥物選項。 |
英文摘要 | Hypertension is an increasingly prevalent cardiovascular risk factor associated with high rates of morbidity and mortality. Patients with hypertension may require a combination of ≥ 2 antihypertensive agents to achieve blood pressure (BP) control. Servikar HCT is a triple combination of olmesartan (OM) 20 mg, amlodipine (AML) 5 mg, and hydrochlorothiazide (HTCZ) 12.5 mg, fixed-dose combination. The aim of this study was to determine a triple combination of Servikar HCT had a clinically significant efficacy and safety in patients with hypertension. We conducted a retrospective study data collected from July 2012 to February 2013. Totally 103 patients who hypertension which were treated with Sevikar HCT,SPSS 17.0 was used for statistical analysis. Results:the 103 patients (52.4% male) had a mean (SD) age of 65.4±13.3 years. At baseline, the mean seated systolic blood pressure (SeSBP)/ seated diastolic blood pressure (SeDBP) was 164.1 ± 20.1/90.6 ± 16.3 mmHg. Diabetes was present in 53.9% of the population, chronic cardiovascular disease 42.7%, and chronic kidney disease 14.5%. The 32 (31.1%) patients with (2 antihypertensive agents) single pill combination plus single agents, 26 (25.2%) with (2 antihypertensive agents) single- pill combination agents, 25 (24.3%) patient take three kinds of single agents . At week 4,8,12, triple combination treatment with significant decrease in SeSBP: -16 vs -16 vs -17 mmHg respectively [P < 0.005]; SeDBP: -8 vs -9 vs -9 mmHg [P < 0.005].The most common adverse events in the triple combination treatment group were peripheral edema (2.91%), gastrointestinal dysfunction (2.91%). In these adult patients with moderate hypertension, triple combination treatment with OM 20 mg + AML 5 mg + HCTZ 12.5 mg was associated with significant BP reductions. It is recommended when blood pressure were difficult to control, fixed-dose combination of antihypertensive drugs provide another option. |
本系統中英文摘要資訊取自各篇刊載內容。